Given this, we treated three different KRASG12C-mutant human cancer cell lines (MiaPaCa-2, H2030, and H358) in triplicate with the vehicle DMSO as a control, the KRASG12C inhibitor AMG510 (sotorasib)4 at a fixed dose of 5 nM, which corresponds to an IC20 to IC30 depending on the cell line, and the PI4KA inhibitor C762 at a fixed dose of 10 nM, which corresponds to the approximate IC30 to IC55, depending on the cell line, or both compounds at these concentrations. Here, PI4KA is linked to cancer.